Paul M. Harari, MD Print Friendly PageChair, Department of Human Oncology
Faculty, University of Wisconsin School of Medicine and Public Health
Dr. Harari’s medical interests include radiation oncology, head and neck oncology, and oncology training and education.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Human Oncology|
Professional Certifications and Education
University of Arizona Medical Center
University of California-Davis Medical Center, Sacramento
University of Virginia, Charlottesville, VA, 1984
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Harari's clinical and laboratory research focuses on treatment advances for head and neck cancer patients through precision radiation techniques and the use of molecular targeted growth inhibitors combined with radiation.
Chung CH Zhang Q Kong CS Harris J Fertig EJ Harari PM Wang D Redmond KP Shenouda G Trotti A Raben D Gillison ML Jordan RC Le QT .
p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2014 Sep 29;
[PubMed ID: 25267748]
Morris ZS Harari PM .
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol. 2014 Sep 10;32(26):2886-93
[PubMed ID: 25113770]
Harari PM Harris J Kies MS Myers JN Jordan RC Gillison ML Foote RL Machtay M Rotman M Khuntia D Straube W Zhang Q Ang K .
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014 Aug 10;32(23):2486-95
[PubMed ID: 25002723]
Cannon DM Geye HM Hartig GK Traynor AM Hoang T McCulloch TM Wiederholt PA Chappell RJ Harari PM .
Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck. 2014 Aug;36(8):1120-5
[PubMed ID: 23804248]
Kimple RJ Harari PM .
Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol. 2014 Jun;50(6):560-4
[PubMed ID: 24134946]
Huang S Peet CR Saker J Li C Armstrong EA Kragh M Pedersen MW Harari PM .
Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers. Mol Cancer Ther. 2013 Dec;12(12):2772-81
[PubMed ID: 24130052]
Hong JC Kruser TJ Gondi V Mohindra P Cannon DM Harari PM Bentzen SM .
Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):290-6
[PubMed ID: 23906930]
Kruser TJ Rice SR Cleary KP Geye HM Tome WA Harari PM Kozak KR .
Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy. Technol Cancer Res Treat. 2013 Oct;12(5):383-9
[PubMed ID: 23547974]
Kimple RJ Smith MA Blitzer GC Torres AD Martin JA Yang RZ Peet CR Lorenz LD Nickel KP Klingelhutz AJ Lambert PF Harari PM .
Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013 Aug 1;73(15):4791-800
[PubMed ID: 23749640]
Kimple RJ Harari PM Torres AD Yang RZ Soriano BJ Yu M Armstrong EA Blitzer GC Smith MA Lorenz LD Lee D Yang DT McCulloch TM Hartig GK Lambert PF .
Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res. 2013 Feb 15;19(4):855-64
[PubMed ID: 23251001]
Huang S Li C Armstrong EA Peet CR Saker J Amler LC Sliwkowski MX Harari PM .
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2013 Jan 15;73(2):824-33
[PubMed ID: 23172311]
Nyflot MJ Harari PM Yip S Perlman SB Jeraj R .
Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol. 2012 Oct;105(1):36-40
[PubMed ID: 23068711]
Hoang T Huang S Armstrong E Eickhoff JC Harari PM .
Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res. 2012 Apr 26;31:37
[PubMed ID: 22538017]
Huang S Benavente S Armstrong EA Li C Wheeler DL Harari PM .
p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 2011 Nov 15;71(22):7071-9
[PubMed ID: 22068033]
Harari PM Hartig GK .
Robotics in head and neck cancer: future opportunities. Oncology (Williston Park). 2010 Oct;24(11):1015, 1020, 1022
[PubMed ID: 21155451]
Wheeler DL Dunn EF Harari PM .
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010 Sep;7(9):493-507
[PubMed ID: 20551942]
Kruser TJ Wheeler DL Armstrong EA Iida M Kozak KR van der Kogel AJ Bussink J Coxon A Polverino A Harari PM .
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res. 2010 Jul 15;16(14):3639-47
[PubMed ID: 20507929]
Harari PM Song S Tomé WA .
Emphasizing conformal avoidance versus target definition for IMRT planning in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):950-8
[PubMed ID: 20378266]
Traynor AM Richards GM Hartig GK Khuntia D Cleary JF Wiederholt PA Bentzen SM Harari PM .
Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck. 2010 May;32(5):599-606
[PubMed ID: 19757422]
Shepard PM Olson J Harari PM Leverson G Hartig GK .
Therapeutic selective neck dissection outcomes. Otolaryngol Head Neck Surg. 2010 May;142(5):741-6
[PubMed ID: 20416466]